MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12883-025-04429-5

Медицинская библиотека · BMC neurology · 2025

Clazosentan for cerebral vasospasm prevention in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.

Abunada Saaed, Ashraf Taimoor, Kumar Dinesh, Moryani Hasnain Ali, Rai Partab, Abbasi Sumiya, Devi Nisha, Turesh Muskan, Dev Shah, Hyder Salman, Aizazuddin Muhammad, Kumar Sateesh, Kumar Laksh, Khan Sidra, Yusuf Salih Abdella

СтатьяСистематический обзорМетаанализПеревод в очереди

Аннотация

BACKGROUND

Aneurysmal subarachnoid hemorrhage (aSAH) remains a devastating neurological emergency, with cerebral vasospasm contributing significantly to poor outcomes. Clazosentan, a selective endothelin-A receptor antagonist, has shown potential in preventing vasospasm, though its overall efficacy and safety profile require comprehensive assessment.

METHODS

We conducted a systematic review and meta-analysis following PRISMA guidelines, searching multiple databases through March 2025. We included randomized controlled trials and observational studies comparing clazosentan with placebo or active controls in aSAH patients. Outcomes included vasospasm incidence, its complications, and adverse events.

RESULTS

Analysis of 13 reports (n = 5,728) were included. Compared to placebo, clazosentan significantly reduced vasospasm-related cerebral infarcts (RR: 0.56, p = 0.0002), delayed ischemic neurological deficits (DIND) (RR: 0.67, p < 0.0001), and the incidence of vasospasm (RR: 0.54, p < 0.00001). Compared to fasudil, clazosentan was associated with a lower incidence of vasospasm (RR: 0.44, p = 0.0004) and vasospasm-related cerebral infarcts (RR: 0.27, p = 0.002), but no significant difference was observed in DIND (p = 0.89). The drug showed particular benefit at higher doses (10-15 mg/h) and in surgical clipping patients. Clazosentan use was linked to a higher risk of adverse events, including pulmonary complications and hypotension (p < 0.05).

CONCLUSION

While clazosentan effectively prevents cerebral vasospasm following aSAH, particularly at higher doses in surgically treated patients, its clinical utility must be weighed against significant systemic adverse effects. These findings support selective use in high-risk patients while highlighting the need for careful monitoring and individualized treatment approaches.

Для цитирования: Abunada Saaed, Ashraf Taimoor, Kumar Dinesh, Moryani Hasnain Ali, Rai Partab, Abbasi Sumiya, Devi Nisha, Turesh Muskan, Dev Shah, Hyder Salman, Aizazuddin Muhammad, Kumar Sateesh, Kumar Laksh, Khan Sidra, Yusuf Salih Abdella. Clazosentan for cerebral vasospasm prevention in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.. BMC neurology. 2025. DOI: 10.1186/s12883-025-04429-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.